Posted innews OB/GYN & Women's Health
Blocking the Prolactin Receptor for Endometriosis Pain: HMI-115 Phase II Shows Dose-Dependent Analgesia Without Hypoestrogenic Effects
A multicenter phase II trial of HMI-115, a human monoclonal antibody against the prolactin receptor, showed dose-dependent reductions in endometriosis-associated pain and preserved ovarian function, supporting larger Phase III evaluation.